# Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

> **NCT06553885** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Enfortumab Vedotin

## Key facts

- **NCT ID:** NCT06553885
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06553885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06553885, "Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06553885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*